Last reviewed · How we verify
NCT05837858
The Human Metabolic Profile and Gut Microbiota Under Various Dietary Quality
NA trial testing whole grain-wheat flour food+standardized meals in Biomarkers in 24 participants. Completed in 24 May 2023.
24 May 2023
Quick facts
| Lead sponsor | Peking University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 24 |
| Start date | 28 April 2023 |
| Primary completion | 24 May 2023 |
| Estimated completion | 24 May 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- whole grain-wheat flour food+standardized meals
- refined wheat flour food+standardized meals
Conditions studied
- Biomarkers — all drugs for Biomarkers →
Sponsor
Peking University
Who can join
Adults 18 to 40, any sex, with Biomarkers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this food intervention study is to screen/validate the whole grain food intake biomarker in health Chinese's population.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05837858
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Biomarkers
Currently open trials in the same condition.
- NCT07012759 — Pleural Effusion Biomarkers in Lung Adenocarcinoma Patients · recruiting
- NCT06717243 — Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS) · recruiting
- NCT06924372 — Application of Salivary Biomarkers in Risk Assessment for Oral Diseases in Children With Type 1 Diabetes · active not recruiting
- NCT07345286 — Clinical Aspects, Management and Surveillance of Febrile Illnesses in DRC · recruiting
- NCT06751251 — The Exploration of OX40 (CD134) Expression Levels in Sarcoma Specimens and Its Clinical Application in Prognosis Determi · active not recruiting
Other Peking University trials
Trials by the same sponsor.
- NCT07519122 — Fangshan Active Nutrition Initiative · NA · not yet recruiting
- NCT07466238 — HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer · NA · recruiting
- NCT07480525 — Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder · NA · not yet recruiting
- NCT07454031 — Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma · Phase 1 · not yet recruiting
- NCT07466225 — HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05837858 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University
- Last refreshed: 3 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05837858.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing